IBBQ · Invesco
Invesco Nasdaq Biotechnology ETF
See how 33 reported holdings combine into this ETF’s P/E and P/S. Market value, signed ordinary earnings and revenue are added before each ratio is calculated.
Holdings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
Core valuation
Coverage is the share of positive eligible-equity holding value represented in each metric. The published holdings account for 100.07% of fund weight. The reliability standard requires at least 90.00% disclosed fund weight and metric coverage, with no individual uncovered holding above 1.00%.
Largest reported holdings
| Holding | Weight | Trailing P/E | Trailing P/S |
|---|---|---|---|
| UTHRUnited Therapeutics Corp. | 6.28% | 18.69× | 7.77× |
| ILMNIllumina, Inc. | 5.37% | 48.63× | 8.93× |
| BIIBBiogen Inc. | 5.05% | 23.98× | 3.31× |
| INCYIncyte Corp. | 4.91% | 16.35× | 4.37× |
| ALNYAlnylam Pharmaceuticals, Inc. | 4.84% | 39.93× | 6.44× |
| REGNRegeneron Pharmaceuticals, Inc. | 4.77% | 17.99× | 5.01× |
| AMGNAmgen Inc. | 4.71% | 25.18× | 5.78× |
| GILDGilead Sciences, Inc. | 4.62% | -56.45× | 6.00× |
| BCRXBioCryst Pharmaceuticals, Inc. | 3.42% | -5.39× | 2.21× |
| CPRXCatalyst Pharmaceuticals, Inc. | 3.30% | 17.41× | 6.46× |
Top 10 of 33 reported holdings. * A holding uses its latest full-year result only when both trailing and latest-quarter inputs are unavailable; open the stock for the exact year end.
Most similar funds
Ranked by shared weight across matching disclosed company holdings and explicitly reported same-currency cash.
- PBE · Invesco Biotechnology & Genome ETF100.00% holdings overlap · US market
- FBT · First Trust NYSE Arca Biotechnology Index Fund44.83% holdings overlap · NYSE Arca
- BBH · VanEck Biotech ETF36.07% holdings overlap · Nasdaq
- IBB · iShares Biotechnology ETF32.73% holdings overlap · US market
- FTXH · First Trust Nasdaq Pharmaceuticals ETF30.64% holdings overlap · Nasdaq
Sources and limitations
Holdings are sourced from Invesco and company financial inputs retain primary-source links. Monetary values are normalised to USD. Corporate actions, reporting lags, unmapped securities and cash can create differences from provider figures.
Open official holdings sourceResearch holdings date: 30 April 2026. Informational research, not investment advice.